2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Doxorubicin
3
pazopanib
2
Trabectedin
2
Ifosfamide
2
Dacarbazine
2
selinexor
1
repotrectinib
1
pembrolizumab
1
eribulin
1
Suspensions
1
Sunitinib
1
Proton Therapy
1
Nivolumab
1
Methotrexate
1
Magnetic Resonance Spectroscopy
1
Histamine H2 Antagonists
1
Fluorodeoxyglucose F18
1
Famotidine
1
FAPI-46
1
Epirubicin
1
Dasatinib
1
Cisplatin
1
Capsules
1
Axitinib
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solitary Fibrous Tumors
×
Histamine H2 Antagonists
×
Clear all
NCT06789172
2026-05-22
INVOKE
Epkin
Phase 1
Recruiting
166 enrolled